Nuclear Matrix Protein 22 as Adjunct to Urine Cytology and Cystoscopy in Follow-up of Superficial TCC of Urinary Bladder

Urology

Volumn 73, Issue 3, 2009, Pages 592-596

  Gupta, Narmada P ^a   Sharma, Nitin ^a   Kumar, Rajeev ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN 22;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CYSTOSCOPY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; URINE;

EID: 60549100513     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.04.051     Document Type: Article

References (20)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics. CA Cancer J Clin 51 (2001) 15-36
2. Abel P.D. Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol 62 (1988) 103-109
3. Hall M.C., Chang S.S., Dalbagni G., et al. Guidelines for the management of non-muscle invasive bladder cancer (stage Ta, T1 and Tis): 2007 update. J Urol 178 (2007) 2314-2330
4. Murphy W.M., Soloway M.S., Jukkola A.F., et al. Urinary cytology and bladder cancer: The cellular features of transitional cell neoplasms. Cancer 53 (1984) 1555-1565
5. Sarosdy M.F., de Vere W.R.W., Soloway M.S., et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 154 (1995) 383-384
6. Soloway M.S., Briggman V., Carpinto G.A., et al. Use of a new tumor marker, urinary NMP-22 in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156 (1996) 363-367
7. Johnston B., Morales A., Emerson L., et al. Rapid detection of bladder cancer: A comparative study of point of care tests. J Urol 158 (1997) 2098-2101
8. Heine B., Hummel M., Muller M., et al. Non-radioactive measurement of telomerase activity in bladder cancer, bladder washings and urine. J Pathol 184 (1998) 71-76
9. Gordan J.N., Shu W.P., Schlussel R.N., et al. Altered extra cellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res 53 (1993) 4971-4977
10. Epstein J.I., Amin M.B., Reuter V.R., et al., Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell neoplasms of the urinary bladder). Am J Surg Pathol 22 (1998) 1435-1448
11. Wiener H.G., Vooijs G.P., and Van't Hof-Grootenboer B. Accuracy of urine cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 37 (1993) 163-169
12. Lokeshwar V.B., and Soloway M.S. Current bladder tumor tests: Does their prolonged utility fulfill clinical necessity?. J Urol 165 (2001) 1067-1077
13. Berezneyr C.D.S. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 60 (1974) 1410-1417
14. Pardoll D.M., Vogelstein B., and Coffey D.S. A fixed site of DNA replication in eukaryotic cells. Cell 19 (1980) 527-536
15. Weiner H.G., Mian C., Haitel A., et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?. J Urol 159 (1998) 1876-1880
16. Ramakumar S., Bhuyian J., Besse J.A., et al. Comparison of screening methods in the detection of bladder cancer. J Urol 161 (1999) 388-394
17. Sharma S., Zippe C.D., Pandrangi L., et al. Exclusion criteria enhance the specificity and positive predictive value of NMP-22 and BTA Stat. J Urol 162 (1999) 53-57
18. Miyanga N., Akaza H., Tsukamoto T., et al. Urinary matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 6 (1999) 173-177
19. Zippe C., Pandrangi L., and Aggarwal A. NMP-22: A sensitive cost-effective test in patients at risk for bladder cancer. Anticancer Res 19 (1999) 2621-2623
20. Rodriguez M.F., Toniolo C.G., Palou J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164 (2000) 690-691